| 1 |
杨玉生, 纪立明. 幽门螺杆菌的危害与防治 [J]. 世界最新医学信息文摘, 2019, 19(34): 315.
|
| 2 |
Sultan S, Ahmed SI, Murad S, et al. Primary versus secondary immune thrombocytopenia in adults; a comparative analysis of clinical and laboratory attributes in newly diagnosed patients in Southern Pakistan [J]. Med J Malaysia, 2016, 71(5): 269-274.
|
| 3 |
Nagy P, Johansson S, Molloy-Bland M. Systematic review of time trends in the prevalence of helicobacter pylori infection in China and the USA [J]. Gut Pathog, 2016, 8: 8.
|
| 4 |
Li RJ, Dai YY, Qin C, et al. Treatment strategies and preventive methods for drug-resistant Helicobacter pylori infection [J]. World J Meta-Anal, 2020, 8(2): 98-108.
|
| 5 |
刘文忠, 谢勇, 陆红, 等. 第五次全国幽门螺杆菌感染处理共识报告 [J]. 胃肠病学, 2017, 22(6): 346-360.
|
| 6 |
Kaye JA, Castellsague J, Bui CL, et al. Risk of acute liver injury associated with the use of moxifloxacin and other oral antimicrobials: a retrospective, population-based cohort study [J]. Pharmacotherapy, 2014, 34(4): 336-349.
|
| 7 |
Bai P, Zhou LY, Xiao XM, et al. Susceptibility of Helicobacter pylori to antibiotics in Chinese patients [J]. J Dig Dis, 2015, 16(8): 464-470.
|
| 8 |
张俊璇, 方超然, 时鑫鑫, 等. 根除幽门螺杆菌治疗药物的研究进展 [J]. 医学综述, 2020, 26(2): 316-321.
|
| 9 |
李珂, 吕冠华. 幽门螺杆菌耐药的中医药研究进展 [J]. 中国民间疗法, 2019, 27(21): 103-105.
|
| 10 |
Ritu K, Anurag K. In-silico design, synthesis, ADMET studies and biological evaluation of novel derivatives of chlorogenic acid against urease protein and H.pylori bacterium [J]. BMC Chemistry, 2019, 13(1): 1-17.
|
| 11 |
Patel A, Shah N, Prajapati JB. Clinical application of probiotics in the treatment of helicobacter pylori infection-a brief review [J]. J Microbiol Immunol Infect, 2014, 47(5): 429-437.
|
| 12 |
Ushiyama A, Tanaka K, Aiba Y, et al. Lactobacillus gasseri OLL2716 as a probiotic in clarithromycin-resistant Helicobacter pylori infection [J]. J Gastroenterol Hepatol, 2003, 18(8): 986-991.
|
| 13 |
王熙苑, 霍丽娟. 幽门螺杆菌感染的治疗新进展 [J]. 国际消化病杂志, 2020, 40(4): 243-245.
|
| 14 |
Chung PY, Khanum R. Antimicrobial peptides as potential anti-biofilm agents against multi-drug resistant bacteria [J]. J Microbiol Immunol Infect, 2017, 50(4): 405-410.
|
| 15 |
Huang Y, Hang X, Jiang X, et al. In vitro and in vivo activities of zinc linolenate, a selective antibacterial agent against helicobacter pylori [J]. Antimicrob Agents Chemother, 2019, 63(6): e00004-19.
|
| 16 |
陈艳, 庄则豪. 非抗生素类药物在幽门螺杆菌根除中的应用 [J]. 胃肠病学和肝病学杂志, 2017, 26(6): 649-652.
|
| 17 |
陈淑婉, 罗廷威, 蒙智扬, 等. 加味半夏泻心汤联合三联疗法治疗寒热错杂型幽门螺杆菌相关性萎缩性胃炎的疗效 [J]. 临床医学, 2020, 40(11): 119-120.
|
| 18 |
黎宏章, 徐雪华, 刘云惠, 等. 难治性幽门螺杆菌胃炎患者的耐药性及根除治疗的研究 [J]. 浙江医学, 2020, 42(12): 1321-1323, 1326.
|
| 19 |
周羽翙, 郑欣晔, 叶梦思, 等. 益生菌辅助含铋剂四联疗法根除幽门螺杆菌的临床研究 [J]. 中国现代医学杂志, 2021, 31(1): 68-73..
|
| 20 |
Kashimura H, Suzuki K, Hassan M, et al. Polaprezinc, a mucosal protective agent, in combination with Lansoprazole, Amoxycillin and Clarithromycin increases the cure rate of helicobacter pylori infection [J]. Aliment Pharmacol Ther, 1999, 13(4): 483-7.
|
| 21 |
谢晚霞. 半夏泻心汤加减治疗慢性胃炎的效果分析 [J]. 基层医学论坛, 2020, 24(17): 2470-2472.
|
| 22 |
徐小青, 周帆, 吴小溪, 等. 黄连素联合四联疗法在幽门螺杆菌一线治疗中的作用研究 [J]. 中国医药导报, 2020, 17(19): 78-81.
|
| 23 |
张美怡, 翟齐啸, 赵建新, 等. 鼠李糖乳杆菌JS-SZ-2-1抗幽门螺杆菌感染的临床效果评价 [J]. 食品与发酵工业, 2020, 46(23): 29-34..
|
| 24 |
杨雪, 高采平, 张颖慧, 等. 嗜酸乳杆菌联合优化四联方案根除难治性幽门螺杆菌的疗效 [J]. 四川医学, 2020, 41(11): 1147-1151.
|
| 25 |
Islek A, Sayar E, Yilmaz A, et al. Bifidobacterium lactis B94plus inulin for Treatment of helicobacter pylori infection in children: does it increase eradication rate and patient compliance? [J]. Acta Gastroenterol Belg, 2015, 78 (3): 282-286.
|
| 26 |
Shen YN, Zou YQ, Chen XN, et al. Antibacterial self-assembled nanodrugs composed of berberine derivatives and rhamnolipids against Helicobacter pylori [J]. J Control Release, 2020, 328: 575-586.
|
| 27 |
Okubo H, Akiyama J, Kobayakawa M, et al. Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility [J]. J Gastroenterol, 2020, 55(11): 1054-1061.
|
| 28 |
何春生, 金峰, 石晋. 聚普瑞锌联合基于克拉霉素三联疗法治疗幽门螺杆菌相关性胃炎的效果 [J]. 中外医学研究, 2018, 16(11): 15-16.
|
| 29 |
董锦文, 戴艳. 黄连素结合三联疗法根除幽门螺杆菌感染的疗效观察 [J]. 临床合理用药杂志, 2013, 6(24): 56-57.
|
| 30 |
司君圣, 胡延丽. 黄连素结合三联疗法根除幽门螺杆菌感染的临床效果观察 [J]. 中国现代药物应用, 2013, 7(15): 10-11.
|
| 31 |
鲁占彪, 王美梅, 陈丽梅. 黄连素结合三联疗法根除幽门螺杆菌感染的临床研究 [J]. 中国现代药物应用, 2013, 7(4): 84-85.
|
| 32 |
陈兢, 张庆霞, 张庆. 黄连素联合三联方案不同疗程治疗幽门螺杆菌的疗效分析 [J]. 长江大学学报(自科版), 2013, 10(36): 1-5.
|
| 33 |
徐小青, 周帆, 吴小溪, 等. 黄连素联合四联疗法在幽门螺杆菌一线治疗中的作用研究 [J]. 中国医药导报, 2020, 17(19): 78-81.
|
| 34 |
石鹏, 姚洁. 黄连素联合四联疗法治疗幽门螺杆菌阳性消化性溃疡的效果及机制探讨 [J]. 中国医药导报, 2019, 16(22): 77-79, 86, 190.
|
| 35 |
张迪, 柯丽, 聂爱英, 等. 黄连素四联方案补救治疗幽门螺杆菌感染的有效性和安全性 [J]. 现代生物医学进展, 2017, 17(3): 464-469.
|
| 36 |
郑硕. 探讨黄连素联合四联疗法治疗幽门螺杆菌(Hp)阳性消化性溃疡的效果及可能机制 [J]. 智慧健康, 2020, 6(26): 96-97, 100.
|